Alle Storys
Folgen
Keine Story von Novasep mehr verpassen.

Novasep

Novasep Acquisition by its Management and by Gilde, Banexi, BNP Paribas has Been Signed on January 9th, 2007

Pompey, France (ots/PRNewswire)

Groupe Novasep has been acquired
for an enterprise value of EUR 425 million by its management and by a
financial investor group composed of Gilde Buy Out, Banexi Capital
Partenaires, BNP Paribas. The acquisition has been signed on November
29th, 2006 and completed on January 9th 2007.
Groupe Novasep will continue to operate through two complementary
divisions contributing to approximately EUR 280 million of sales.
Novasep Synthesis offers custom synthesis services utilising niche
technologies to produce elaborate molecules for the pharmaceutical
industry, as well as producing and marketing proprietary products,
typically generics. Novasep Process is a recognised leader in the
field of chromatography, with particular strength in continuous
processes. It provides turn-key physical purification solutions to
industrial biotech, pharmaceutical and the growing bio-pharma
industries. Headquartered in Pompey (France), Novasep operates mainly
in Europe, with subsidiaries in the United States, China and Japan
and 1300 employees working in nine sites.
About Groupe Novasep
Groupe Novasep, with its headquarters near Nancy (in eastern
France), works with the pharmaceutical, food, cosmetics,
agrochemicals, and specialty chemicals industries through its two
business segments - Novasep Process and Novasep Synthesis. Both
strategic businesses are complementary organisations with skills
designed to provide technically optimised and economical solutions
for the life-science sector and related industries.
Novasep Process specialises in solving purification challenges for
the Pharmaceutical, Biopharmaceutical and Industrial Biotech markets.
The company offers laboratory purification equipment as well as
large-scale industrial production plants for producing pure products,
and a full range of services including process development, multi-ton
scale custom purification and performance optimisation.
To serve its different markets, Novasep Process offers innovative
and reliable solutions based on Novasep Process proprietary
technologies : Novasep chromatography (high and low pressure) and
crystallisation, Applexion(r) ion exchange and evaporation, Orelis(r)
membrane processes.
Novasep Synthesis provides R&D and custom synthesis, from lab to
industrial scale, with special expertise in hazardous chemistry ,
chiral chemistry, early stage services and highly potent APIs. It
includes Dynamit Nobel, Finorga and Séripharm.
Press contact
    Jean-Marc Le Rudulier
    Marketing & Communication Director
    Groupe Novasep
    Bd de la Moselle
    B.P. 50
    54340 Pompey
    France
    Tel: +33-3-83-49-71-46
    Fax: +33-3-83-49-71-40
     jean-marc.le.rudulier@novasep.com
www.novasep.com

Contact:

Press contact: Jean-Marc Le Rudulier, Marketing & Communication
Director, Tel : + 33-3-83-49-71-46, Fax : + 33-3-83-49-71-40,
jean-marc.le.rudulier@novasep.com

Weitere Storys: Novasep
Weitere Storys: Novasep
  • 14.12.2006 – 20:15

    Solvay Pharmaceuticals and Novasep Have Signed a Strategic Manufacturing Alliance

    Pompey, France (ots/PRNewswire) - Solvay Pharmaceuticals and Novasep have signed a five-year strategic manufacturing alliance which includes the exclusive synthesis of two active pharmaceutical ingredients for Solvay Pharmaceuticals. Solvay and Novasep have recently set a strategic manufacturing alliance defining Novasep as a preferred partner for the ...

  • 31.03.2006 – 18:22

    Thierry Favreau Appointed President of Novasep Process

    Pompey, France (ots/PRNewswire) - Groupe Novasep is pleased to announce that Mr Thierry Favreau has been appointed President of its Novasep Process business. Thierry graduated from EDHEC and held several management and senor executive positions within Baxter, Becton Dickinson and Sanofi-Synthelabo. Prior to joining Groupe Novasep Thierry Favreau was CEO of Stedim Group.. "Growth will be driven by the ...